TY - JOUR
T1 - Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide
AU - Reichart, Florian
AU - Maltsev, Oleg V.
AU - Kapp, Tobias G.
AU - Räder, Andreas F.B.
AU - Weinmüller, Michael
AU - Marelli, Udaya Kiran
AU - Notni, Johannes
AU - Wurzer, Alexander
AU - Beck, Roswitha
AU - Wester, Hans Jürgen
AU - Steiger, Katja
AU - Di Maro, Salvatore
AU - Di Leva, Francesco Saverio
AU - Marinelli, Luciana
AU - Nieberler, Markus
AU - Reuning, Ute
AU - Schwaiger, Markus
AU - Kessler, Horst
N1 - Publisher Copyright:
© 2019 American Chemical Society.
PY - 2019/2/28
Y1 - 2019/2/28
N2 - Integrins play important roles in physiological and pathophysiological processes. Among the RGD-recognizing integrin subtypes, the αvβ8 receptor is emerging as an attractive target because of its involvement in various illnesses, such as autoimmune diseases, viral infections, and cancer. However, its functions have, so far, not been investigated in living subjects mainly because of the lack of a selective αvβ8 ligand. Here, we report the design and potential medical applications of a cyclic octapeptide as the first highly selective small-molecule ligand for αvβ8. Remarkably, this compound displays low nanomolar αvβ8 binding affinity and a strong discriminating power of at least 2 orders of magnitude versus other RGD-recognizing integrins. Peptide functionalization with fluorescent or radioactive labels enables the selective imaging of αvβ8-positive cells and tissues. This new probe will pave the way for detailed characterization of the distinct (patho)physiological role of this relatively unexplored integrin, providing a basis to fully exploit the potential of αvβ8 as a target for molecular diagnostics and personalized therapy regimens.
AB - Integrins play important roles in physiological and pathophysiological processes. Among the RGD-recognizing integrin subtypes, the αvβ8 receptor is emerging as an attractive target because of its involvement in various illnesses, such as autoimmune diseases, viral infections, and cancer. However, its functions have, so far, not been investigated in living subjects mainly because of the lack of a selective αvβ8 ligand. Here, we report the design and potential medical applications of a cyclic octapeptide as the first highly selective small-molecule ligand for αvβ8. Remarkably, this compound displays low nanomolar αvβ8 binding affinity and a strong discriminating power of at least 2 orders of magnitude versus other RGD-recognizing integrins. Peptide functionalization with fluorescent or radioactive labels enables the selective imaging of αvβ8-positive cells and tissues. This new probe will pave the way for detailed characterization of the distinct (patho)physiological role of this relatively unexplored integrin, providing a basis to fully exploit the potential of αvβ8 as a target for molecular diagnostics and personalized therapy regimens.
UR - https://www.scopus.com/pages/publications/85062276822
U2 - 10.1021/acs.jmedchem.8b01588
DO - 10.1021/acs.jmedchem.8b01588
M3 - Article
C2 - 30657681
AN - SCOPUS:85062276822
SN - 0022-2623
VL - 62
SP - 2024
EP - 2037
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 4
ER -